Five things for pharma marketers to know for Thursday morning

Five things for pharma marketers to know

• The Supreme Court agreed to review a lower court decision that would make mifepristone, the commonly used abortion pill, less accessible.

• Poison control centers across the U.S. said they are seeing a steep increase in calls related to semaglutide, with some people reporting symptoms related to accidental overdoses.

• A thought leadership piece detailed how Pfizer’s $43 billion acquisition of Seagen may impact the broader biotech market.

• Editas Medicine agreed to license Vertex Pharmaceuticals its Cas9 gene editing technology for ex vivo gene editing medicines targeted at sickle cell disease and beta thalassemia.

• Acadia Pharmaceutical won a patent suit against MSN Laboratories regarding its Parkinson’s disease drug Nuplazid.